A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic ma...
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibi...
Fenofibrate for Prevention of DR Worsening
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately s...
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
This study aims to evaluate the ocular and systemic safety, tolerability and efficacy of RO7446603 in participants with diabetic macular edema (DME). The study consists of 2 segments: Phase I (Parts 1...
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
This study is open to adults 18 and older with an eye condition called diabetic macular edema. People are required to have a specific type of diabetic macular edema called centre-involved diabetic mac...
A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy
This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study. The purpose of this study is to find ou...
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME....
A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01
The goal of this clinical trial is to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of VX-01 as stand-alone treatment for Diabetic Retinopathy of Non-Proliferative Typ...
Top Cities for Diabetic Retinopathy Clinical Trials
Diabetic Retinopathy clinical trials are recruiting across 41 cities. Here are the cities with the most active studies:
About Diabetic Retinopathy
Diabetic retinopathy is a diabetes complication that affects the blood vessels in the retina and is the leading cause of blindness in working-age adults. Diabetic macular edema (DME) involves fluid accumulation in the macula. Treatment includes anti-VEGF injections, laser therapy, and blood sugar control.
Clinical trials are advancing new treatments for diabetic retinopathy. Currently, 8 studies are recruiting a combined 3,428 participants across the United States. Research is being conducted by 7 organizations including EyeBiotech Ltd., Hoffmann-La Roche, Jaeb Center for Health Research and 4 others.
2026 Diabetic Retinopathy Research Landscape
As of March 2026, the diabetic retinopathy clinical trial landscape includes 8 actively recruiting studies across 41 cities in the United States. These studies are collectively seeking 3,428 participants, with an average enrollment target of 429 per study.
Research is being led by 7 different organizations, including EyeBiotech Ltd., Hoffmann-La Roche, Jaeb Center for Health Research, Genentech, Inc., Boehringer Ingelheim, and 2 others.
Geographically, diabetic retinopathy trials are most concentrated in Phoenix, Arizona (9 trials); Encino, California (5 trials); Sacramento, California (4 trials); Beverly Hills, California (4 trials); Pasadena, California (4 trials) and 7 other cities.
Featured Diabetic Retinopathy Studies
Highlighted recruiting studies for diabetic retinopathy, selected by enrollment size and research scope.
A Study of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
EYE-RES-103 is a randomized, double masked pivotal study to evaluate the efficacy and safety of 2 dose levels of EYE103 in comparison with the active control, ranibizumab, in patients with diabetic macular edema (DME). In the first year, all 3 treatment groups will be treated every 4 weeks with either EYE103 or ranibizumab. Beginning at Year 2, the frequency of treatment for participants will shi...
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 weeks (Q24W) compared with intravitreal (IVT) ranibizumab 0.5 milligrams (mg) every 4 weeks (Q4W). The substudy will evaluate safety of re-implanting the updated PDS with ranibizumab and the refill-exchange procedures following re-implantation in part...
Fenofibrate for Prevention of DR Worsening
This randomized trial will evaluate the effect of fenofibrate compared with placebo for prevention of diabetic retinopathy (DR) worsening through 6 years of follow-up in eyes with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at baseline. In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model for ophthalmologists to prescribe or collaborat...
Frequently Asked Questions About Diabetic Retinopathy Clinical Trials
Are there diabetic retinopathy clinical trials near me?
Yes, there are 8 diabetic retinopathy clinical trials currently recruiting across 41+ cities in the United States, including Phoenix, Arizona; Encino, California; Sacramento, California. Browse the studies above to find one at a location convenient for you.
How do I join a diabetic retinopathy clinical trial?
To join a diabetic retinopathy clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are diabetic retinopathy clinical trials free?
Yes, participation in diabetic retinopathy clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of diabetic retinopathy treatments are being studied?
Current diabetic retinopathy clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 7 research organizations.
Is it safe to participate in diabetic retinopathy clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov